Deric Park, MD
Diagnostic Neuroimaging · Chicago, ILNPI 1730391509
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,400 of the $6,864 with a category attached, or 78.7%. Novocure Inc. accounts for 95.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $6,036 and has fallen 95.3% since, to $281 in 2025.
Across 26 payments — averaging $263.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$7K
- SK Life Science, Inc.$147
- Servier Pharmaceuticals LLC$35
- Merck$34
- Johnson & Johnson$32
- Caris MPI, Inc.$27
- plus $30 from 2 others
Across 12 payments — averaging $6691.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$52K
- Agios Pharmaceuticals, Inc.$28K
What the payments were for
- Speaking & faculty fees$5,40079%
- Travel & lodging$1212%
- Food & beverage$1,32519%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 16 | $6,558 |
| SK Life Science, Inc. | 1 | $147 |
| Servier Pharmaceuticals LLC | 2 | $35 |
| Merck | 2 | $34 |
| Johnson & Johnson | 2 | $32 |
| Caris MPI, Inc. | 1 | $27 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$5,964
- Optune Gio$151
- Oncology$135
How this compares
Too few diagnostic neuroimaging providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 63 | $1,046 |
| Ondansetron Hcl | 20 | $980 |
| Lacosamide | 23 | $712 |
| Dexamethasone | 41 | $590 |
| Famotidine | 19 | $177 |
| Duloxetine Hcl | 14 | $175 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $88 |
Paid to pharmacies, not to this prescriber.
Other diagnostic neuroimaging in Chicago
- Sri Preethi GunnalaChicago$32K
- Elie BarakatChicago$12K
- Mustafa MafrajiChicago$3K
- Jeremy JonesChicago$167
- Sreeshma TellapuriChicago$127
- Phillip EpsteinWheeling$95
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.